Tag: FOLR1
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...
Refined Dosing Strategy for IMGN853 Achieves Objective
Data presented at the annual meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA. shows clinical activity with IMGN853 (ImmunoGen), an antibody drug conjugate or ADC currently in Phase I clinical testing for the treatment of folate receptor α (FRα)-positive cancers, including ovarian, endometrial, lung and other cancers, starting at doses of 3.3 mg/kg.
